Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enema is a hypertonic saline solution used as a stimulant laxative for the evacuation of the lower bowel.
## Primary Indications
* Bowel preparation prior to colonoscopy or surgery.
* Relief of occasional constipation.
## Adult Dosing
* **Bowel Preparation:** Typically, one 4.5 oz (133 mL) enema administered no more than 24 hours before the procedure. Follow specific institutional protocols, which may include a second dose.
* **Constipation:** One 4.5 oz (133 mL) enema administered as a single dose.
## Pediatric Dosing
* **Ages 12 years and older:** Same as adult dosing.
* **Ages 2-11 years:** 2.25 oz (66.5 mL) enema.
* **Under 2 years:** Contraindicated due to increased risk of hyperphosphatemia, hypocalcemia, and seizures.
## Dose Adjustments
No specific dose adjustments for hepatic or renal impairment are typically recommended for this short-term, rectal administration. However, caution is advised in patients with pre-existing renal impairment due to the potential for sodium and phosphate absorption.
## Contraindications
* Congenital or acquired megacolon.
* Heart failure, congestive heart failure, or other conditions predisposing to fluid retention.
* Renal impairment.
* Children under 2 years of age.
* Patients with ileus or bowel obstruction.
* Patients with gastrointestinal perforation or toxic megacolon.
* Known hypersensitivity to sodium phosphate.
## Adverse Effects
Common: Abdominal cramping, nausea, vomiting, bloating, rectal irritation.
Serious:
* **Hyperphosphatemia:** Especially in children, elderly, or those with renal impairment. Symptoms include tetany, muscle cramps, paresthesias, and cardiac arrhythmias.
* **Hypocalcemia:** Can occur secondary to hyperphosphatemia.
* **Electrolyte Imbalance:** Hyponatremia, hyperkalemia, dehydration.
* **Renal injury:** Acute tubular necrosis has been reported.
* **Seizures:** Particularly in pediatric patients.
## Key Drug Interactions
* **Diuretics (thiazide and loop):** Increased risk of hypernatremia and dehydration.
* **ACE inhibitors and ARBs:** Increased risk of hyperkalemia.
* **Calcium channel blockers:** Increased risk of hyperkalemia.
* **Drugs affecting renal function:** May increase the risk of hyperphosphatemia and renal injury.
## Monitoring
* Monitor for signs and symptoms of electrolyte imbalance (e.g., muscle cramps, weakness, confusion, dizziness).
* Assess for signs of dehydration.
* Renal function may be monitored in patients with risk factors.
## Clinical Pearls
* Ensure patient is well-hydrated before and after administration.
* Advise patients to retain the enema for the recommended time (usually 5 minutes) for maximum effectiveness.
* This product is for rectal use only. Do not administer orally.
* Avoid use in patients with impaired gag reflex or those who are unconscious or semiconscious.
---
*This information is intended for healthcare professionals. Always consult the official prescribing information and institutional guidelines for the most current and complete drug information.*
